| Name | Title | Contact Details |
|---|
American Associated Pharmacies and H. D. Smith combined respective pharmacy services administrative organizations (PSAO) into a new PSAO, servicing more than 2,300 independent retail pharmacies across the United States. Arete Pharmacy Network will combine and succeed H. D. Smith`s Third Party Network and AAP`s United Drugs. Arete Pharmacy Network focuses on independents and community pharmacies, with a focus on managed care contracting and expanded tools and services, allows pharmacies to deliver quality care as a differentiator in their communities. Arete Pharmacy Network can help effectively manage the financial, quality and operational aspects of your pharmacy business.
Serán Bioscience is a contract development and manufacturing organization (CDMO) that provides drug development services to the pharmaceutical industry, including chemistry, formulation, spray drying, dosage form, analytical, and GMP manufacturing serv...
It is the goal of Women's International Pharmacy, Inc. to provide excellent service and quality compounded prescriptions to our customers. At Women's International Pharmacy, Inc., we are dedicated to providing custom compounded doses of bioidentical
Let’s operate. We prioritize you, so you can prioritize patients. Trusted brands like Quill, Sharpoint, and Tachosil.
Momenta is a biotechnology company with a product pipeline of both complex mixture generic and novel drugs. Our complex mixture generics and follow-on biologics effort is focused on building a thorough understanding of the structure-process-activity of complex mixture drugs to develop generic versions of marketed products. While we use a similar analytical and development approach across all of our product candidates, we tailor that approach for each specific product candidate. Our first objective is to apply our core analytical technology to thoroughly characterize the structure of the marketed product. By defining the chemical composition of multiple batches of a marketed product, we are able to develop an equivalence window which captures the inherent variability of the innovator`s manufacturing process. Using this information, we then build an extensive understanding of the structure-process relationship to design and control our manufacturing process to manufacture reproducibly an equivalent version of the marketed product. Where necessary, and as required by the U.S. Food and Drug Administration, or FDA, we will supplement an application with additional supportive structure-activity data (e.g., immunogenicity, pharmacodynamics). Our goal is to obtain FDA approval for and commercialize generic or follow-on versions of complex mixture products, thereby providing high quality, safe and affordable medicines to patients in need.